APEC1621A NCI-COG Pediatric Match (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions

NCT03213704

NCI-COG Pediatric Match (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of LOXO-101 (Larotrectinib) in Patients with Tumors Harboring Actionable NTRK Fusions

Associated Conditions

Cancer, Companion Study

Principal Investigator

Sponsor

Children's Oncology Group

The overall goal of this study is to test any good and bad effects of the study drug LOXO-101 (larotrectinib) on your tumor.